Achieving Glucose Balance in Type 2 Diabetes: Targeted Pharmacotherapy [Enduring Webinar- Previously Recorded]

Faculty

Curtis L. Triplitt, PharmD, CDE

Assistant Professor

Department of Medicine

Division of Diabetes

University of Texas Health Science Center

San Antonio Texas Diabetes Institute

San Antonio, Texas

Activity Overview

Type 2 diabetes mellitus accounts for 80% to 90% of cases of diabetes in the United States. These patients often present as adults, although increasing rates of obesity are leading to onset of the disease in adolescents and children. Type 2 diabetes represents a large number of different primary genetic and environmental insults leading to relative insulin deficiency—an imbalance of insulin production and insulin requirements.

This pre-recorded activity will provide pharmacists with a review of the available and emerging pharmacologic treatments for achieving glucose balance and how each medication addresses the numerous metabolic deficits seen in patients with diabetes.

Learning Objectives

At the conclusion of this educational activity, participants should be able to:

1. Describe mechanism of action of currently available pharmacologic options for the management of type 2 diabetes

2. Address the pharmacologic target and outcome associated with each medication

3. Review emerging antidiabetic agents, their role in diabetes management, and how they will address defects in glucose regulation

Release date: January 25, 2012

Expiration date: January 25, 2014

Type of Activity: Knowledge

Fee: None

Length of Webinar: 1 hour including a question-and-answer session

Target Audience: Pharmacists

Grant Support

This activity is supported by an educational grant from Bristol-Myers Squibb and AstraZeneca LP.

Pharmacy Credit

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.1 CEU) under the ACPE universal activity number 0290-0000-11-061-H01-P. The activity is available for CE credit through January 25, 2014.

Important: If you received CE credit for the live version of this program held on January 25, 2012, you cannot receive additional CE credit for this enduring version.

How to Obtain Credit

To receive their statement of credit, participants must view the webinar in its entirety and complete the online evaluation form and online posttest with a score of 70% or better. After successful completion of the online evaluation form and posttest, participants may immediately print their statement of credit.

Disclosure Policy

According to the disclosure policies of the Pharmacy Times Office of Continuing Professional Education, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with commercial companies related to this activity. If a conflict is identified, it is the responsibility of the Pharmacy Times Office of Continuing Professional Education to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty and planning staff have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Curtis L.Triplitt, PharmD, CDE, has disclosed the following relevant financial relationships with commercial interests:

Consultant/Advisory Board: Roche, Takeda Pharmaceuticals

Speaker’s Bureau: Amylin, Eli Lilly, Pfizer

The American Journal of Managed Care

Planning staff—Jeff Prescott, PharmD, RPh, Ida Delmendo, Kara L. Guarini, MS, and Christina Doong, have no relevant financial relationships with commercial interests to disclose related to this activity.

Pharmacy Times Office of Continuing Professional Education

Planning staff—Judy V. Lum, MPA, Elena Beyzarov PharmD, and Donna W. Fausak have no relevant financial relationships with commercial interests to disclose related to this activity

This CE lesson is contained in the following video/webinar formats:

• Achieving Glucose Balance in Type 2 Diabetes: Targeted Pharmacotherapy (WMV - 109.4 MB)
• Achieving Glucose Balance in Type 2 Diabetes: Targeted Pharmacotherapy (MP4 - 68.7 MB)

This CE lesson is contained in the following PDF slides:

• Achieving Glucose Balance in Type 2 Diabetes: Targeted Pharmacotherapy (PDF - 2.8 MB)

A transcription of the webinar's Q&A session is available in a downloadable file:

• Achieving Glucose Balance in Type 2 Diabetes: Targeted Pharmacotherapy Q&A (PDF - 90 KB)

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

Professional Disclaimer

The information in this presentation is intended for educational use and to stimulate professional discussion among colleagues. It should not be construed as legal advice. There is no way such a brief discussion of an issue or topic for educational or discussion purposes can adequately and fully address the multifaceted and often complex issues that arise in the course of professional practice. Moreover, statutes, regulations, and court interpretations of the law can vary from jurisdiction to jurisdiction. It is always the best advice for a pharmacist to seek counsel from an attorney who can become thoroughly familiar with the intricacies of a specific situation and render advice in accordance with the full information.

For questions about this Internet CPE activity, please contact ceinfo@pharmacytimes.com.

System Requirements

PC-based participants

Required: Windows® 7, Vista, XP, 2003 Server or 2000

Macintosh®-based participants

Required: Mac OS® X 10.4.11 (Tiger®) or newer